Tarsus Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Tarsus Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $94.11. The average 1-year stock price forecast is 58.54% higher than the current stock price, while the lowest is $88 (+48.25%) and the highest is $100 (+68.46%).

Price Target: $94.11 (+58.54%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$88	$94.11	$95	$100
Change	+48.25%	+58.54%	+60.04%	+68.46%

Analyst Ratings

The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	8	7	7	8	8	8
Buy	1	1	1	1	1	1
Hold	1	1	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	10	9	8	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jenna Davidner Barclays	Barclays	Buy Maintains $100	Buy	Maintains	$100	+68.46%	May 15, 2026
Francois Brisebois LifeSci Capital	LifeSci Capital	Buy Reiterates $95	Buy	Reiterates	$95	+60.04%	May 9, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $100	Buy	Reiterates	$100	+68.46%	May 8, 2026
Eddie Hickman Guggenheim	Guggenheim	Buy Reiterates $90	Buy	Reiterates	$90	+51.62%	May 8, 2026
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Buy Reiterates $88	Buy	Reiterates	$88	+48.25%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

696.36M

from 451.36M

54.28%

from 451.36M

Revenue Next Year

904.52M

from 696.36M

29.89%

from 696.36M

EPS This Year

-0.59

from -1.59

EPS Next Year

2.87

from -0.59

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	57.03M	25.82M	17.45M	182.95M	451.36M	696.36M
Revenue Growth	-	-54.73%	-32.42%	948.62%	146.71%	54.28%
Gross Profit	13.24M	-17.76M	-34.46M	116.74M	356.35M	647.96M
Gross Margin	23.22%	-68.81%	-197.50%	63.81%	78.95%	93.05%
Operating Income	-12.16M	-62.71M	-143.16M	-120.57M	-70.97M	-29.57M
Net Income	-13.83M	-62.09M	-135.89M	-115.55M	-66.42M	-28.48M
EPS	-	-	-	-	-1.59	-0.59
Free Cash Flow	4.74M	-27.35M	-74.49M	-50.48M	-164.00K	-55.15M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	704.3M
Avg	696.4M
Low	688.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	56.0%
Avg	54.3%
Low	52.4%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.59
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-